<DOC>
	<DOCNO>NCT02011763</DOCNO>
	<brief_summary>The aim study describe safety profile Avaxim 80U Pediatric , order confirm good safety profile vaccine . Primary objective : - To describe safety Avaxim 80U Pediatric dose vaccine administer 6 month apart , subject age 12 month 15 year .</brief_summary>
	<brief_title>Safety Two Doses Avaxim® 80U Pediatric ( Inactivated Hepatitis A Vaccine ) Toddlers , Children Adolescents</brief_title>
	<detailed_description>Eligible participant age 12 month 15 year 5 month ( 185 month ) enrollment receive two dos vaccine prevention hepatitis A ( 6 month apart ) , follow safety 30 day second vaccination .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<criteria>Aged 12 185 month ( approximately 15 year 5 month ) day inclusion Informed consent form sign date subject age 12 year old ( base local regulation ) , informed consent form sign dated parent ( ) another legally acceptable representative Subject parent / legally acceptable representative able attend schedule visit comply trial procedure Subjects age less 2 year : Born full term pregnancy ( ≥ 37 week ) and/or birth weight ≥ 2.5 kg . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation time study enrollment ( 4 week precede first trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination plan receipt vaccine 4 week precede follow trial vaccination Previous vaccination Hepatitis A either trial vaccine another Hepatitis A vaccine Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History Hepatitis A infection , confirm either clinically , serologically , microbiologically At high risk hepatitis A infection trial Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Selfreported thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness / infection ( accord investigator judgment ) day vaccination febrile illness ( axillary temperature ≥ 37.1°C ) . A prospective subject include study condition resolve febrile event subside Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hepatitis A</keyword>
	<keyword>hepatitis A virus</keyword>
	<keyword>Avaxim® 80U Pediatric</keyword>
</DOC>